High-dose (HD) recombinant IL2 therapy has been shown to be effective and has been approved by the Food and Drug Administration (FDA) for the treatment of renal cell carcinoma and metastatic melanoma [4]. The gene discussed is IL2; the disease is hereditary clear cell renal cell carcinoma.